|
Iglesias-Perez C, Jimenez-Fonseca P, Lopez Robles J, Garcia Adrian S, Fernandez Perez I, Martinez Del Prado P, Rubio Perez J, Martinez de Castro E, Diaz Pedroche C, Garcia de Herreros M, Carmona Campos M, Ruperez Blanco AB, Salgado Fernandez M, Quintanar Verduguez T, Marrupe Gonzalez D, Covela Rua M, Santiago Crespo JA, Nieva Munoz M, Munoz A, Carmona-Bayonas A. Venous thrombosis in lung cancer compared with other tumors: results from the TESEO-SEOM registry. Thromb Res. 2025 Dec;256:109525. doi: 10.1016/j.thromres.2025.109525. Epub 2025 Nov 3. PubMed PMID: 41237754.
AÑO: 2025; IF: 3.4
|
41237754
|
Carmona-Bayonas A, Alvarez-Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MA, Garcia-Centeno R, Iglesias C, Garcia-Donas J, Picon MJ, Paja M, Gonzalez Batanero L, Garcia L, Alonso Gordoa T, Lopez C, Hanzu F, Martinez-Trufero J, Febrero B, Saiz-Lopez P, Blanco Carrera C, Ramon Y Cajal T, Veiguela B, Gressani O, Valdes N, Jimenez-Fonseca P. Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry. J Clin Endocrinol Metab. 2025 Oct 16;110(11):3155-3167. doi: 10.1210/clinem/dgaf082. PubMed PMID: 39988973.
AÑO: 2025; IF: 5.1
|
|
Obispo B, Calderon C, Carmona-Bayonas A, Ghanem I, Cano-Cano JM, Jimenez-Fonseca P. The role of baseline and persistent depression in adjuvant cancer therapy: impact on toxicity and quality of life. Int J Clin Health Psychol. 2025 Oct-Dec;25(4):100640. doi: 10.1016/j.ijchp.2025.100640. Epub 2025 Oct 17. PubMed PMID: 41146968; PubMed Central PMCID: PMC12554112.
AÑO: 2025; IF: 4.4
|
|
Jimenez-Fonseca P, Alvarez-Escola C, Ballester Navarro I, Hernando Cubero J, Gonzalez Fernandez L, Mangas Cruz MA, Iglesias C, Garcia-Donas J, Picon MJ, Paja M, Gonzalez Batanero L, Garcia L, Molina J, Jimeno Mate R, Aller J, Romero MDCT, Cardenas Salas J, Gutierrez-Buey G, Egana Zunzunegui N, Navarro M, Lecumberri MJ, Valdes N, Carmona-Bayonas A. External validation of the S-GRAS score for predicting recurrence in patients with adrenocortical carcinoma: implications for adjuvant mitotane therapy. Eur J Endocrinol. 2025 Jul 31;193(2):320-328. doi: 10.1093/ejendo/lvaf171. PubMed PMID: 40810251.
AÑO: 2025; IF: 5.2
|
|
Capdevila J, Tafuto S, Krogh M, Teule A, Garcia-Carbonero R, Klumpen HJ, Cremer B, Sevilla I, Eriksson B, Tabaksblat E, Metges JP, Reed NS, Schrader J, Navarro V, Valenti V, Hernando J, Colao AM, Vestermark L, Carnaghi C, Knigge UP, Jimenez-Fonseca P, Benavent M, de Vos-Geelen J, Venerito M, Von Werder A, Jann H, Rinke A, Smith D, Horsch D, Starling N, Ruszniewski P, Baudin E, Caroli-Bosc FX, Manzano JL, Martin M, Scarpa A, Lawlor RT, Ragulan C, Ps H, Sadanandam A, Carmona-Bayonas A, Salazar R. Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial. ESMO Open. 2025 Dec;10(12):105922. doi: 10.1016/j.esmoop.2025.105922. Epub 2025 Dec 2. PubMed PMID: 41337860; PubMed Central PMCID: PMC12720089.
AÑO: 2025; IF: 8.3
|